沐舒坦雾化吸入联合丙种球蛋白静脉滴注治疗新生儿肺炎的效果

Mucosolvin combined with gamma globulin for neonatal pneumonia

目的探讨沐舒坦雾化吸入联合丙种球蛋白静脉滴注治疗新生儿肺炎的效果。方法采用随机数字表法将80例新生儿肺炎患儿分为对照组和观察组，各40例。对照组在常规治疗方案中应用沐舒坦雾化吸入治疗，观察组在常规治疗方案中应用沐舒坦雾化吸入及丙种球蛋白静脉滴注治疗。对比两组临床治疗价值。结果接受治疗后，观察组发热时间、咳嗽时间、湿哕音时间及住院总时间均短于对照组（P〈0．05）；而入组接受治疗前及治疗5d后，两组PaO2、PaCO2比较，差异无统计学意义（P〉0．05）。同时，入组接受治疗前，两组CRP、CD3＋及CD4＋比较，差异无统计学意义（P〉0．05）；治疗5d后，观察组CRP低于对照组，CD3＋、CD4＋高于对照组（P〈0．05）。此外，观察组治疗总有效率明显高于对照组，差异有统计学意义（P〈0．05）。结论沐舒坦雾化吸入联合丙种球蛋白静脉滴注治疗新生儿肺炎可有效改善患儿CRP水平及临床治疗效果。

Objective To study the effect of mucosolvin combined with gamma globulin for neonatal pneumonia. Methods With random number table method, 80 cases of neonatal pneumonia were divided into a control group and an observation group, 40 for each group. Both groups were routinely treated; in addition the control group took atomization inhalation of mucosolvin and the observation group took atomization inhalation of mucosolvin and were intravenously dripped gamma globulin. The clinical values were compared between these two groups. Results After the treatment, the times of fever, cough, and wet rale and total hospital stay were shorter in the observation group than in the control group （P〈0.05）. There were no statistical differences in PaO2 and PaCO2 before and 5 days after the treatment between these two groups （P〉0.05）. There were no statistical differences in CRP, CD3＋, and CD4＋ between these two groups before the treatment （P〉0.05）; 5 days after the treatment, the CRP was lower and the CD3＋ and CD4＋ were higher in the observation group than in the control group （P〈0.05）. The total efficacy was significantly higher in the observation group than in the control group （P〉0.05）. Conclusions Mucosolvin combined with gamma globulin for neonatal pneumonia can effectively improve the CRP level and clinical therapeutic effect.